Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Tomosyn-2 is required for normal motor performance in mice and sustains neurotransmission at motor endplates.

Geerts CJ, Plomp JJ, Koopmans B, Loos M, van der Pijl EM, van der Valk MA, Verhage M, Groffen AJ.

Brain Struct Funct. 2015 Jul;220(4):1971-82. doi: 10.1007/s00429-014-0766-0. Epub 2014 Apr 18.

PMID:
24744148
2.

Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc1638N mice.

Bakker ER, Das AM, Helvensteijn W, Franken PF, Swagemakers S, van der Valk MA, ten Hagen TL, Kuipers EJ, van Veelen W, Smits R.

Carcinogenesis. 2013 Nov;34(11):2629-38. doi: 10.1093/carcin/bgt215. Epub 2013 Jun 12.

PMID:
23764752
3.

Induced Wnt5a expression perturbs embryonic outgrowth and intestinal elongation, but is well-tolerated in adult mice.

Bakker ER, Raghoebir L, Franken PF, Helvensteijn W, van Gurp L, Meijlink F, van der Valk MA, Rottier RJ, Kuipers EJ, van Veelen W, Smits R.

Dev Biol. 2012 Sep 1;369(1):91-100. doi: 10.1016/j.ydbio.2012.06.007. Epub 2012 Jun 9.

4.

Evidence for complete epistasis of null mutations in murine Fanconi anemia genes Fanca and Fancg.

van de Vrugt HJ, Koomen M, Bakker S, Berns MA, Cheng NC, van der Valk MA, de Vries Y, Rooimans MA, Oostra AB, Hoatlin ME, Te Riele H, Joenje H, Arwert F.

DNA Repair (Amst). 2011 Dec 10;10(12):1252-61. doi: 10.1016/j.dnarep.2011.09.015. Epub 2011 Oct 28.

PMID:
22036606
5.

β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis.

van Veelen W, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER, Franken PF, van Gurp L, Meijlink F, van der Valk MA, Kuipers EJ, Fodde R, Smits R.

Gut. 2011 Sep;60(9):1204-12. doi: 10.1136/gut.2010.233460. Epub 2011 Feb 9.

6.

Early morbidity encountered in the dietary-related mouse model of Barrett's esophagus: a question of zinc?

Grotenhuis BA, Franken PF, Swinkels WJ, Boonstra A, van der Valk MA, van Lanschot JJ, Fodde R.

Dis Esophagus. 2011 Jul;24(5):371-3. doi: 10.1111/j.1442-2050.2010.01151.x. Epub 2010 Dec 17.

PMID:
21166735
7.

Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.

van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.

FASEB J. 2011 Jan;25(1):280-9. doi: 10.1096/fj.10-163709. Epub 2010 Sep 27.

PMID:
20876209
8.

Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia.

Tsaalbi-Shtylik A, Verspuy JW, Jansen JG, Rebel H, Carlée LM, van der Valk MA, Jonkers J, de Gruijl FR, de Wind N.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21836-41. doi: 10.1073/pnas.0909507106. Epub 2009 Dec 10.

9.

Adenomatous polyposis coli-mediated control of beta-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors.

Miclea RL, Karperien M, Bosch CA, van der Horst G, van der Valk MA, Kobayashi T, Kronenberg HM, Rawadi G, Akçakaya P, Löwik CW, Fodde R, Wit JM, Robanus-Maandag EC.

BMC Dev Biol. 2009 Apr 8;9:26. doi: 10.1186/1471-213X-9-26.

10.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH.

J Clin Invest. 2007 Nov;117(11):3583-92.

11.

An inducible mouse model of melanoma expressing a defined tumor antigen.

Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, Song JY, Inderberg-Suso EM, Schmitt-Verhulst AM, Berns A, Van den Eynde BJ.

Cancer Res. 2006 Mar 15;66(6):3278-86.

12.

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Beijnen JH.

Br J Cancer. 2003 Nov 3;89(9):1776-82.

13.

Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions.

Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, van Oers MH, van Lier RA.

Nat Immunol. 2003 Jan;4(1):49-54. Epub 2002 Dec 9. Erratum in: Nat Immunol. 2003 Mar;4(3):295.

PMID:
12469117
14.

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH.

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15649-54. Epub 2002 Nov 12.

15.

Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice.

Koomen M, Cheng NC, van de Vrugt HJ, Godthelp BC, van der Valk MA, Oostra AB, Zdzienicka MZ, Joenje H, Arwert F.

Hum Mol Genet. 2002 Feb 1;11(3):273-81.

PMID:
11823446
16.

Immunotherapy through TCR gene transfer.

Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN.

Nat Immunol. 2001 Oct;2(10):957-61.

PMID:
11577349
17.
18.

Defective spectrin integrity and neonatal thrombosis in the first mouse model for severe hereditary elliptocytosis.

Wandersee NJ, Roesch AN, Hamblen NR, de Moes J, van der Valk MA, Bronson RT, Gimm JA, Mohandas N, Demant P, Barker JE.

Blood. 2001 Jan 15;97(2):543-50.

PMID:
11154235
19.

Mice with a targeted disruption of the Fanconi anemia homolog Fanca.

Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, Joenje H, Berns A, Arwert F.

Hum Mol Genet. 2000 Jul 22;9(12):1805-11.

PMID:
10915769
20.
21.

Long-term effects of total-body irradiation on the kidney of Rhesus monkeys.

van Kleef EM, Zurcher C, Oussoren YG, Te Poele JA, van der Valk MA, Niemer-Tucker MM, van der Hage MH, Broerse JJ, Robbins ME, Johnston DA, Stewart FA.

Int J Radiat Biol. 2000 May;76(5):641-8.

PMID:
10866286
22.

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

van Helvoort A, de Brouwer A, Ottenhoff R, Brouwers JF, Wijnholds J, Beijnen JH, Rijneveld A, van der Poll T, van der Valk MA, Majoor D, Voorhout W, Wirtz KW, Elferink RP, Borst P.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11501-6.

23.

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).

Kuin A, Rutgers M, van der Valk MA, Beijnen JH, Smets LA.

Br J Cancer. 1999 Feb;79(5-6):802-6.

24.

High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14.

Fijneman RJ, Jansen RC, van der Valk MA, Demant P.

Cancer Res. 1998 Nov 1;58(21):4794-8.

25.

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH.

Clin Cancer Res. 1998 Oct;4(10):2293-7.

27.

Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine.

Kuin A, Aalders M, van der Valk MA, Frey A, Schmidt HH, Smets LA.

Cancer Chemother Pharmacol. 1998;42(1):37-45.

PMID:
9619756
28.

Targeted disruption of the beta1 integrin gene in a lymphoma cell line greatly reduces metastatic capacity.

Stroeken PJ, van Rijthoven EA, van der Valk MA, Roos E.

Cancer Res. 1998 Apr 1;58(7):1569-77.

29.

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028-33.

30.

Gene interaction and single gene effects in colon tumour susceptibility in mice.

van Wezel T, Stassen AP, Moen CJ, Hart AA, van der Valk MA, Demant P.

Nat Genet. 1996 Dec;14(4):468-70.

PMID:
8944029
31.

Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene.

Smit JJ, Baas F, Hoogendijk JE, Jansen GH, van der Valk MA, Schinkel AH, Berns AJ, Acton D, Nooter K, Burger H, Smith SJ, Borst P.

J Neurosci. 1996 Oct 15;16(20):6386-93.

32.

Different genetic susceptibility to aberrant crypts and colon adenomas in mice.

Moen CJ, van der Valk MA, Bird RP, Hart AA, Demant P.

Cancer Res. 1996 May 15;56(10):2382-6.

33.

Human multidrug resistance 3-P-glycoprotein expression in transgenic mice induces lens membrane alterations leading to cataract.

Dunia I, Smit JJ, van der Valk MA, Bloemendal H, Borst P, Benedetti EL.

J Cell Biol. 1996 Feb;132(4):701-16.

34.

Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity.

Driessens MH, Stroeken PJ, Rodriguez Erena NF, van der Valk MA, van Rijthoven EA, Roos E.

J Cell Biol. 1995 Dec;131(6 Pt 2):1849-55.

35.

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.

Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.

Cancer Res. 1995 Jun 15;55(12):2627-34.

36.

Genetic dissection of susceptibility to radiation-induced apoptosis of thymocytes and mapping of Rapop1, a novel susceptibility gene.

Mori N, Okumoto M, van der Valk MA, Imai S, Haga S, Esaki K, Hart AA, Demant P.

Genomics. 1995 Feb 10;25(3):609-14.

PMID:
7759093
37.

Photosensitizing efficacy of MTHPC-PDT compared to photofrin-PDT in the RIF1 mouse tumour and normal skin.

van Geel IP, Oppelaar H, Oussoren YG, van der Valk MA, Stewart FA.

Int J Cancer. 1995 Jan 27;60(3):388-94.

PMID:
7829249
38.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al.

Cell. 1994 May 20;77(4):491-502.

PMID:
7910522
39.

Partial protection of photodynamic-induced skin reactions in mice by N-acetylcysteine: a preclinical study.

Baas P, Oppelaar H, van der Valk MA, van Zandwijk N, Stewart FA.

Photochem Photobiol. 1994 Apr;59(4):448-54.

PMID:
8022887
40.
41.

The recombinant congenic strains--a novel genetic tool applied to the study of colon tumor development in the mouse.

Moen CJ, van der Valk MA, Snoek M, van Zutphen BF, von Deimling O, Hart AA, Demant P.

Mamm Genome. 1991;1(4):217-27.

PMID:
1686571
42.

Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.

Baldew GS, McVie JG, van der Valk MA, Los G, de Goeij JJ, Vermeulen NP.

Cancer Res. 1990 Nov 1;50(21):7031-6.

43.

Fetal mouse alveolar type II cells in culture express several type II cell characteristics found in vivo, together with major histocompatibility antigens.

Oomen LC, Ten Have-Opbroek AA, Hageman PC, Oudshoorn-Snoek M, Egberts J, van der Valk MA, Calafat J, Demant P.

Am J Respir Cell Mol Biol. 1990 Oct;3(4):325-39.

PMID:
1698401
44.

Triploidy and intersexuality in adult commercial layers.

Frankenhuis MT, van Walsum J, de Boer LE, Dieleman SJ, Misdorp W, van der Valk MA, Wensing CJ.

Avian Pathol. 1990 Jan;19(1):3-14.

PMID:
18679909
45.

Glucocorticoid hormone effect on transplacental carcinogenesis and lung differentiation: influence of histocompatibility-2 complex.

Oomen LC, van der Valk MA, Hart AA, Demant P.

J Natl Cancer Inst. 1989 Apr 5;81(7):512-7.

PMID:
2921775
46.

Influence of mouse major histocompatibility complex (H-2) on N-ethyl-N-nitrosourea-induced tumor formation in various organs.

Oomen LC, van der Valk MA, Hart AA, Demant P, Emmelot P.

Cancer Res. 1988 Dec 1;48(23):6634-41.

47.

Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice.

Andres AC, van der Valk MA, Schönenberger CA, Flückiger F, LeMeur M, Gerlinger P, Groner B.

Genes Dev. 1988 Nov;2(11):1486-95.

48.

Different int-1 region DNA rearrangements within different zones of a single mouse mammary tumor.

Sluyser M, Moncharmont B, van der Valk MA, de Goeij CC, Evers SG.

Virology. 1988 Mar;163(1):11-8. Erratum in: Virology 1990 Feb;174(2):630.

PMID:
2831652
49.

Conditional oncogenicity of perfused adriamycin in the tourniquet-isolated rat limb.

Van't Hoff SC, van Dijk WJ, Buys WJ, Van der Valk MA, Benckhuijsen C.

Carcinogenesis. 1986 Oct;7(10):1787-9.

PMID:
3757178
50.

Supplemental Content

Loading ...
Support Center